Aulos Bioscience Phase 2 Results Show Imneskibart Activity in Melanoma and NSCLC
Aulos Bioscience Unveils Encouraging New Phase 2 Data Highlighting Imneskibart’s Clinical Activity in Melanoma and Non–Small Cell Lung Cancer Aulos Bioscience, a clinical-stage immuno-oncology company advancing next-generation immune-modulating therapies, has…
FASENRA Delays Disease Flares in Phase III HES Trial
AstraZeneca’s FASENRA Demonstrates Statistically Significant Clinical Benefit in Phase III NATRON Trial for Hypereosinophilic Syndrome AstraZeneca has announced positive full results from its pivotal Phase III NATRON clinical trial evaluating…
Indapta Highlights Clinical Activity of Allogeneic NK Therapy in R/R Multiple Myeloma
Indapta Therapeutics Showcases Promising Clinical Activity of IDP-023 Allogeneic g-NK Cell Therapy in Relapsed/Refractory Multiple Myeloma at SITC 2025 Indapta Therapeutics, Inc., a privately held, clinical-stage biotechnology company focused on…
Synthekine Reports Positive Early Phase 1 Results for STK-012 Combo in First-Line PD-L1-Negative NSCLC
Synthekine Unveils Encouraging Early Clinical Results for STK-012 in Combination Therapy for First-Line PD-L1–Negative Non-Squamous NSCLC at SITC 2025 Synthekine Inc., a biotechnology company advancing a new generation of engineered…
Gilead Shares New Findings from Phase 3 ASCENT-07 Trial
Gilead Shares Update on Phase 3 ASCENT-07 Trial Evaluating Trodelvy in HR+/HER2-Negative Metastatic Breast Cancer Gilead Sciences, Inc. (Nasdaq: GILD) has released new clinical findings from its Phase 3 ASCENT-07…
Mirum Highlights LIVMARLI® and Volixibat Data at AASLD Liver Meeting®
Mirum Pharmaceuticals Spotlights Advancements in Rare Liver Disease With New Data From LIVMARLI® and Volixibat Programs at AASLD’s The Liver Meeting® 2025 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biotechnology company…
Biomunex Showcases MAIT Engager Preclinical Data at 2025 SITC
Biomunex to Present Preclinical Data on MAIT Engager Platform at 2025 SITC Annual Meeting Biomunex Pharmaceuticals, an innovative French biopharmaceutical company advancing the next generation of antibody-based immunotherapies, announced that…
Northwell Study Shows Promising Seizure Reduction for Chronic Epilepsy Patients
Northwell Study Offers Nuanced Hope for Long-Term Seizure Reduction in Chronic, Treatment-Resistant Epilepsy For millions of individuals worldwide, epilepsy remains one of the most challenging chronic neurological disorders to manage.…
Ondex Automation Buys PlantOPS Consulting to Boost Life Sciences
ONDEX Automation Acquires PlantOPS Consulting, Expands MES and Life Sciences Capabilities ONDEX Automation has announced the acquisition of PlantOPS Consulting, a well-established specialist in Manufacturing Execution System (MES) consulting and…
Mirum Pharmaceuticals Announces Q3 2025 Financial Results and Business Highlights
Mirum Pharmaceuticals Announces Third Quarter 2025 Results and Highlights Strong Commercial Execution, Pipeline Advancement, and Strategic Positioning for 2026–2027 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company dedicated to transforming…
Stoke Therapeutics Announces Q3 2025 Results & Business Update
Stoke Therapeutics Reports Third Quarter 2025 Results and Highlights Clinical and Corporate Progress Toward Transformational RNA Medicines Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering the use of RNA-based…
Catalent Showcases SMARTag® ADC Pipeline at World ADC San Diego
Catalent Showcases SMARTag® ADC Pipeline Progress and New Enhanced Conjugate Class at 16th World ADC San Diego Catalent, Inc., a global leader in contract development and manufacturing services for advanced…